Payment overview · 2025
General Payments
$258.74
3 reported records · 2 companies
Healthcare provider profile · identity verified
Cesar Augusto Ramirez Astacio, M.D
Allopathic & Osteopathic Physicians|General Practice · NEW IBERIA, LA · NPI 1336359033
Verified facts
What the public records show
CMS Open Payments records show Cesar Augusto Ramirez Astacio, M.D received $258.74 in general payments during 2025 across 3 reported records.
RxSight Inc accounted for 59.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| RxSight Inc | Unresolved — no canonical attribution shown | $153.36 | 59.3% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $105.38 | 40.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $258.74 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $153.36 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $153.36 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $153.36 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $153.36 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $153.36 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $105.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 962 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 683 | 139 |
| Furosemide | Furosemide | 592 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 582 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 549 | 79 |
| Gabapentin | Gabapentin | 518 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 507 | 107 |
| Donepezil Hcl | Donepezil Hcl | 413 | 58 |
| Carvedilol | Carvedilol | 400 | 88 |
| Potassium Chloride | Potassium Chloride | 399 | 76 |
| Memantine Hcl | Memantine Hcl | 389 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 354 | 85 |
| Sertraline Hcl | Sertraline Hcl | 340 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 317 | 92 |
| Trazodone Hcl | Trazodone Hcl | 298 | 57 |
| Lisinopril | Lisinopril | 285 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 271 | 30 |
| Mirtazapine | Mirtazapine | 265 | 40 |
| Famotidine | Famotidine | 263 | 35 |
| Losartan Potassium | Losartan Potassium | 254 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 213 | 36 |
| Omeprazole | Omeprazole | 195 | 26 |
| Levetiracetam | Levetiracetam | 189 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 171 | 35 |
| Xarelto | Rivaroxaban | 162 | 18 |
| Buspirone Hcl | Buspirone Hcl | 152 | 29 |
| Metformin Hcl | Metformin Hcl | 150 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 19 |
| Finasteride | Finasteride | 142 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 142 | 34 |
| Montelukast Sodium | Montelukast Sodium | 136 | 20 |
| Latanoprost | Latanoprost | 131 | 19 |
| Tradjenta | Linagliptin | 128 | 12 |
| Baclofen | Baclofen | 121 | 19 |
| Ezetimibe | Ezetimibe | 115 | 15 |
| Farxiga | Dapagliflozin Propanediol | 114 | 22 |
| Simvastatin | Simvastatin | 114 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 112 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 31 |
| Prednisone | Prednisone | 110 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 105 | 24 |
| Humulin R | Insulin Regular, Human | 103 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 15 |
| Entresto | Sacubitril/Valsartan | 100 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 28 |
| Olanzapine | Olanzapine | 92 | 13 |
| Cefdinir | Cefdinir | 90 | 78 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 90 | 17 |
| Sucralfate | Sucralfate | 90 | 25 |
| Myrbetriq | Mirabegron | 86 | suppressed |
| Valsartan | Valsartan | 86 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 84 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 12 |
| Jardiance | Empagliflozin | 77 | suppressed |
| Risperidone | Risperidone | 77 | suppressed |
| Meloxicam | Meloxicam | 76 | suppressed |
| Allopurinol | Allopurinol | 74 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 19 |
| Spironolactone | Spironolactone | 72 | 20 |
| Warfarin Sodium | Warfarin Sodium | 70 | 15 |
| Midodrine Hcl | Midodrine Hcl | 69 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | 11 |
| Tramadol Hcl | Tramadol Hcl | 67 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 34 |
| Linzess | Linaclotide | 66 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 62 | suppressed |
| Bupropion Xl | Bupropion Hcl | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Novolin R | Insulin Regular, Human | 57 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 12 |
| Alprazolam | Alprazolam | 51 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 26 |
| Glipizide | Glipizide | 50 | suppressed |
| Clonidine | Clonidine | 48 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 47 | 13 |
| Ranolazine Er | Ranolazine | 47 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 47 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 17 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 43 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Digoxin | Digoxin | 39 | 12 |
| Bupropion Hcl | Bupropion Hcl | 38 | suppressed |
| Cyclosporine | Cyclosporine | 38 | suppressed |
| Brilinta | Ticagrelor | 37 | suppressed |
| Metolazone | Metolazone | 37 | 12 |
| Nifedipine Er | Nifedipine | 37 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 30 |
| Restasis | Cyclosporine | 36 | suppressed |
| Nystatin | Nystatin | 35 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | 12 |
| Mupirocin | Mupirocin | 33 | 19 |
| Timolol Maleate | Timolol Maleate | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 16 |
| Calcitriol | Calcitriol | 31 | suppressed |
| Hydroxyurea | Hydroxyurea | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 17 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Dexamethasone | Dexamethasone | 25 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Lacosamide | Lacosamide | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 22 | suppressed |
| Flurbiprofen Sodium | Flurbiprofen Sodium | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Mirabegron Er | Mirabegron | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 14 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Estradiol | Estradiol | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Acetic Acid | Acetic Acid | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $258.74 · 3 records | RxSight Inc | LIGHT ADJUSTABLE LENS (LAL), NUPLAZID, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD) | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error